Navigation Links
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Date:8/31/2007

eing investigated to address LDL-C, HDL-C and triglycerides simultaneously in a single pill, which could improve convenience and lipid outcomes.

Abbott will continue executing the clinical trial program and be responsible for regulatory registration of the new combination therapy. AstraZeneca will hold the New Drug Application. Following successful completion of the clinical program, a regulatory application for the new combination therapy is targeted for submission in 2009. This collaboration relates to the US market.

About ABT-335

ABT-335 is a next-generation fenofibrate in clinical development for abnormal lipids in the bloodstream, including cholesterol and triglycerides. In addition, based on the positive results from ABT-335's clinical trial program, Abbott plans to file ABT-335 as a monotherapy (as an adjunct to diet) by the end of 2007. Abbott is currently evaluating ABT-335 as a

co-administered therapy with other on-market statins, including CRESTOR, and expects to present data from the clinical trials in the first half of 2008.

About CRESTOR(R)

CRESTOR (rosuvastatin calcium) is a once-daily, lipid-lowering agent prescription medication for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. It is a member of the statin (HMG-CoA reductase inhibitors) class of drug therapy. CRESTOR has not been determined to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 10 mg. However, initiation of therapy with 5 mg once daily should be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy, and for special populations such as patients taking cyclosporine, Asian patients, and patients with severe renal insufficiency. For patients with marked hypercholestero
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 You,re visiting ... checkup and cleaning when he or she says you ... probably heard before, you may have several questions and ... be relieved to know it,s nothing to worry about. ... patients, questions and alleviate any anxiety the public may ...
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... 19, 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch ... pleased to provide this review of the Company,s recent ... "Over this past year, we achieved many ... extremely proud to say that Monarch America is in ... has ever been," stated Eric Hagen , CEO ...
Breaking Medicine Technology:Root Canals Have Become More Routine 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... Mass., Sept. 16, 2011 Hologic, Inc. (Hologic or ... developer, manufacturer and supplier of premium diagnostic products, medical ... healthcare needs of women, will focus on two new, ... International Papillomavirus Conference & Clinical Workshop (IPV) ...
... Siemens has appointed Kurt D. Bettenhausen Senior Vice ... research & development (R&D) division. Siemens Corporate Research ... emerging technologies, including new imaging processes that allow ... efficiency to reduce building energy consumption, and renewable ...
Cached Medicine Technology:Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 2Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 3Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 4Siemens Appoints New R&D Head for the U.S. 2
(Date:12/22/2014)... Explorys, the leader in big data-driven ... team: Greg Yarrington as Vice President of Operations, Adam ... as Vice President of Solutions. These new leaders are ... in 2015 to support client demand for the company’s ... and growth of its partner network. , Since ...
(Date:12/22/2014)... 22, 2014 In recognition of Veteran’s ... to Hero Reward, a local organization that provides services ... , Located on a couple hundred acres in ... offers lodging, world class fishing, hunting, hiking, horseback riding, ... founded several years ago to support U.S. Service men ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Xarelto ... federal panel of judges has granted a request to ... the U.S. District Court, Eastern District of Louisiana. The ... order on December 12 to transfer over 50 Xarelto ... districts to the Louisiana court for consolidation under U.S. ...
(Date:12/22/2014)... Dallas, Texas (PRWEB) December 22, 2014 Luxury ... with Community Partners of Dallas to provide logistics ... A Dallas-based company, Peacock Alley has a long history of ... works. The additional sponsors of this year's Toy Drive were ... time to give back than the holidays. Providing gifts to ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... colonised by E. coli bacteria early in life have ... a study of infants carried out at the Sahlgrenska Academy at ... outnumber the cells in our bodies by a factor of ten ... maturation of the immune system. The normal bacterial flora in the ...
... 2012) Autism Speaks is pleased to announce the launch ... in Toddlers, or M-CHAT. The M-CHAT is a scientifically validated ... age to assess their risk for autism spectrum disorder (ASD). ... Fein, Ph.D. and clinical psychologist Marianne Barton, Ph.D. The American ...
... Scientists who found a way to make white fat behave ... new obesity treatments. Brown fat burns energy (preventing obesity), ... cells are associated with fat accumulation around organs in the ... an increased risk for diabetes and heart disease, the researchers ...
... participation in a brief training program designed to ... in how patients perceived their interactions with the ... empathy with patients usually drops during medical school ... of Massachusetts General Hospital (MGH) researchers will appear ...
... against serious pneumococcal disease does not offer full protection, ... of Gothenburg, Sweden, finding that the number of cases ... Each year an estimated 1 million children worldwide die ... those in poor countries, but pneumococcal bacteria cause disease ...
... 6, 2012) - Eye color may be an indicator of ... A study, led by the University of Colorado School of ... have vitiligo. It then follows, according to scientists, that people ... Vitiligo is an autoimmune skin disease in which pigment loss ...
Cached Medicine News:Health News:Gut flora affects maturation of B cells in infants 2Health News:Automated autism screening tool available on Autism Speaks website 2Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: